Tyler Van Buren

can you discuss what regions in the U.S. you are seeing the greatest uptake so far in the launch

are you guys starting to see off-label use in the frontline in advance of formal approval given the very positive readouts and the NCCN recommendation

for anito-cel, could the filing happen any day or in the very near future? What is left that's required for the filing

whether you expect the early prescriptions to trend linearly from here or if it's still very early in what is expected to be a more of an exponential launch curve

For Trodelvy, is the lower demand quarter over quarter due to bladder coming out or lower demand in breast

what led to the 16% year-over-year PrEP market growth and acceleration for 2024 that you highlighted

can you remind us what it is powered for? And perhaps more importantly, can you give us your latest thoughts on what constitutes success

is it still possible that higher vaccine efficacy threshold from the first interim could still be reached from the final analysis due to a wide confidence interval

can you discuss your willingness to work on life cycle expansion efforts within the Sanofi collaboration

would you say that these 2 areas in addition to oncology will remain a bigger focus than the 3 others

Can you elaborate on the probability of the late December decision on the RVO and every 4-week dosing filing

there was a great quarter-over-quarter rebound in EYLEA HD. So curious to hear what you would attribute that to

the EYLEA HD CRL for the pre-filled syringe, can you elaborate further on the question posed by the FDA

why you guys decided to institute the dividend now as opposed to when the Sanofi development balance is paid off